<DOC>
	<DOC>NCT00919451</DOC>
	<brief_summary>Study 1B: Ciclosporin in the management of steroid resistant Type 1 Reactions in Leprosy Objective: A pilot study assessing the efficacy and safety of Ciclosporin as a second -line drug in patients with Type 1 Reactions who have not responded to a 12 week course of Prednisolone.</brief_summary>
	<brief_title>Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy</brief_title>
	<detailed_description />
	<mesh_term>Leprosy</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Individuals with clinical evidence of Type 1 Reaction who have not responded to 3 months Prednisolone Treatment Aged 1865 Weigh more than 30Kg Unwillingness to give informed consent Patients with severe active infections such as tuberculosis Pregnant or breastfeeding women (see Appendix II) Those with renal failure, abnormal renal function, hypertensive Patients taking thalidomide currently or within the last 3 months Patients not willing to return for followup Women of reproductive age not willing to use contraception for the duration of the study ( see Appendix II) HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Leprosy</keyword>
	<keyword>Type 1 Reaction</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Ciclosporin</keyword>
</DOC>